Zhejiang Meidishen Biomedical Co., Ltd.

Primary objective: To conduct a bioequivalence study using ilaprazole enteric-coated tablets (5 mg) held by Zhejiang Medishen Biopharmaceutical Co., Ltd. as the test preparation and ilaprazole enteric-coated tablets (trade name: Yilian, specification: 5 mg) held by Livzon Pharmaceutical Factory of Livzon Group as the reference preparation according to the relevant provisions of the bioequivalence study, and to compare the bioequivalence of the two preparations under fasting and postprandial conditions after a single dose. Secondary objective: To evaluate the safety of a single oral dose of the test preparation (ilaprazole enteric-coated tablets, T) and the reference preparation (Yilian, R) in healthy adult subjects in China.

The main purpose of the study is to study the pharmacokinetic characteristics of the test preparation Dydrogesterone Tablets (Specification: 10 mg, licensed by Zhejiang Medishen Biopharmaceutical Co., Ltd.) and the reference preparation Dydrogesterone Tablets (Duphaston®/Duphaston®, Specification: 10 mg; produced by Abbott Biological B.V.) in healthy female participants after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. Secondary purpose of the study is to study the safety of the test preparation Dydrogesterone Tablets (Specification: 10 mg) and the reference preparation Dydrogesterone Tablets (Duphaston®/Duphaston®, Specification: 10 mg) in healthy female participants.

The main purpose of the study: According to the relevant provisions of bioequivalence tests, the perindopril amlodipine tablets (III) (trade name: Kaisuda®, specification: 10mg/5mg) licensed by Les Laboratoires Servier was selected as the reference preparation, and the test preparation perindopril amlodipine tablets (III) (specification: 10mg/5mg) licensed by Zhejiang Medishen Biopharmaceutical Co., Ltd. was tested on fasting and postprandial human bioequivalence, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary purpose of the study: To observe the safety of oral administration of the test preparation perindopril amlodipine tablets (III) (specification: 10mg/5mg) and the reference preparation perindopril amlodipine tablets (III) (trade name: Kaisuda®, specification: 10mg/5mg) in healthy volunteers.